Evidence map›Paper›PMID 39734901›Full record

ArticleMedical journal, Armed Forces India2024

Case of COVID-19 infection-induced complement-mediated thrombotic microangiopathy.

Atul Kumar Srivastava, Sanjay Panda

Abstract readCase Reports
In one paragraph

Article in Medical journal, Armed Forces India, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Atul Kumar SrivastavaClassified Specialist (Medicine) & Nephrologist, Base Hospital Delhi Cantt, New Delhi, India.
Sanjay PandaSenior Advisor (Medicine) & Nephrologist, Base Hospital Delhi Cantt, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 virus can cause thrombotic microangiopathy (TMA) by alternate pathway activation. We present a case of a young female patient who presented with fever and dialysis-dependent acute kidney injury. On evaluation, she was diagnosed with COVID-19-induced complement-mediated thrombotic microangiopathy (CM-TMA). She was initially managed with plasma exchange (PLEX). However, because of poor response to PLEX, she was administered Inj Eculizumab. She became dialysis independent and had normal renal function on follow-up visits.

Indexed as

COVID-19 infectionEculizumabHemolytic uremic syndrome

Identifiers

PMID39734901
PMCPMC11670704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.